Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
EAN 2022
CMSC 2022
ESOC 2022
AAN 2022
CONy 2022
AD/PD 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Trial Updates
1:06
Clinical trials of BTK inhibitors in MS
Celia Oreja-Guevara
• 24 Feb 2022
2:20
Update: novel disease-modifying treatments in development for Huntington’s disease
Anne Rosser
• 23 Sep 2021
8:23
REPAIR-MS and REPAIR-PD: tackling disease progression with gold nanocrystals
Robert Glanzman
• 13 Oct 2021
4:34
Updates on RADIUS-R & RADIUS-P: elezanumab for patients with relapsing and progressive forms of MS
Bruce Cree
• 21 Oct 2021
1:32
Phase II and III studies of CNM-Au8 in ALS
Robert Glanzman
• 13 Oct 2021
3:57
Using virtual placebo to assess long-term effect of siponimod on disability progression in SPMS
Bruce Cree
• 21 Oct 2021
2:44
Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD
Bruce Cree
• 21 Oct 2021
5:10
PREVENT study: eculizumab in AQP4-IgG-positive NMOSD
Kazuo Fujihara
• 4 Oct 2021
2:24
Symptomatic treatment of NMOSD
Kazuo Fujihara
• 4 Oct 2021
3:08
Updates on SWIFT DIRECT: bridging thrombolysis vs direct mechanical thrombectomy
Jan Gralla
• 4 Oct 2021
1:26
PD_PAL: developing new standards of palliative care in Parkinson’s disease
Victor McConvey
• 13 Sep 2021
5:44
Diagnostic criteria and treatment updates for NMOSD
Kazuo Fujihara
• 4 Oct 2021
2:15
VISIONARY-MS update: bioenergetic nanocatalysts under investigation as a novel DMT in RRMS
Robert Glanzman
• 13 Oct 2021
4:37
Phase III SPARX3 trial of moderate- vs. high-intensity exercise to slow progression in PD
Daniel Corcos
• 23 Sep 2021
4:19
The impact of LCIG on dyskinesia duration & severity in PD
Alfonso Fasano
• 22 Sep 2021
3:26
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman
• 15 Oct 2021
Previous
1
2
3
4
5
6
7
8
9
…
14
Next